UroToday

The Optimal Treatment for Gleason Score 9-10 Prostate Cancer

Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...
UroToday

Long-Term Follow-Up of Neoadjuvant Enzalutamide Plus Androgen Deprivation Therapy in Localized Prostate Cancer: A Secondary Analysis of a Neoadjuvant Feasibility Trial.

Neoadjuvant intense androgen deprivation therapy (ADT) with androgen receptor signaling inhibitors (ARSIs) has shown pathologic complete responses (pCR) in prostate cancer (PCa), but long-term ...
UroToday

ASCO 2021: VISION Study Results – Phase III Study of Lutetium-177-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer

(UroToday.com) In this presentation, Dr. Michael Morris presented the results of the phase 3 VISION trial evaluating the radiopharmaceutical lutetium-PSMA (Lu-PSMA) in patients with metastatic ...
UroToday

EAU 2021: Apalutamide for Metastatic Castration-Sensitive Prostate Cancer: Outcomes in High-Volume and Low-Volume Disease From the TITAN Final Analysis

(UroToday.com) At the metastatic prostate cancer session at the European Association of Urology 2021 Virtual Meeting, Dr. Simon Chowdhury presented results of outcomes in high and low-volume disease ...